Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
about
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenAromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenCombination anastrozole and fulvestrant in metastatic breast cancerPrevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesManagement of hot flashes in women with breast cancerAdvances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapyTreatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancerNewer therapies for the treatment of metastatic breast cancer: a clinical updateDiverse roles of SIRT1 in cancer biology and lipid metabolismOptimal management of breast cancer in the elderly patient: current perspectivesReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantClinical utilities of aromatase inhibitors in breast cancerReduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice.The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.Aromatase inhibitor strategies in metastatic breast cancer.Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activitiesGefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.Anastrozole in the management of breast cancer.Sequencing of hormonal therapy in breast cancer.A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerAromatase inhibitors for treatment of postmenopausal patients with breast cancer.A roundtable discussion of aromatase inhibitors as therapy for breast cancer.Protein biomarkers for the early detection of breast cancer.Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?Clinical utility of exemestane in the treatment of breast cancerAromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?Aromatase inhibitors: possible future applications.Endocrine therapy for early breast cancer.Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.Paracrine and endocrine effects of adipose tissue on cancer development and progression.Letrozole in advanced breast cancer: the PO25 trial.Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.Molecularly targeted therapies for breast cancer.Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer
P2860
Q24239985-AE525930-B5A5-45C1-9719-F7BCAFC79053Q24246391-4CE2F006-05F7-4A5D-93FE-49FE591D27EFQ24595386-C1A1FB22-CC41-4614-AACE-A868BE204B62Q24633010-006F3170-7D59-4B5E-BC2C-E53B119F7D3DQ24644229-2C9448AB-40ED-472B-AA25-1CA4B2BC33CCQ24803990-97239D96-42F1-46E0-91E7-1D71EAC90A56Q26741153-E22D0188-E3EC-429A-BBE1-FC97C767B56EQ26865260-9293EFCB-2981-4C9A-86AD-1B48E96142D8Q26997827-800C1C6F-9996-4FC7-8977-87B19AFC622AQ27690879-023C8963-9F28-40AE-838C-CD0D73EAF75EQ28076777-D9515DF2-4187-4A5E-BF88-78B4B306C6EBQ28081168-9222890F-8749-4844-AF3F-D22892D3C437Q30419961-0BC5E221-8645-4D6A-93A0-7BE377725A5AQ33202606-4F58949E-913E-456E-9941-9311765AC440Q33468636-77172524-CA73-4D18-9AAA-D75724ABEBC6Q33705490-E464F889-C10D-4504-BB04-4BA8DC12E4A6Q34156603-CFDB22A5-714C-4308-B852-3FC2911A2D64Q34272016-1ED12A52-82C6-4F3F-8FB8-09AF3DF6AA59Q34466243-5CC66A57-92ED-477A-9767-CB3CFDA8D1A0Q34781067-2F0F1436-401D-4CE0-A36A-7A3EA2C844B8Q34789155-E4C0BF9D-56E0-4BD4-AEA3-D49B02C58A05Q34975951-38125C01-DD37-4F35-8C73-D7BC468AF20BQ35034708-F7485CBF-E1F4-4528-8980-5821F166AA6FQ35117738-5A2D7DAE-8D73-46A9-BF19-B572DC94CB7BQ35129669-3389090D-85FE-48FB-8C58-DD38CCBBA382Q35367572-48C24B1B-5201-4889-AFB7-51CD5F3F5AFBQ35440357-8AF2E977-2AB6-4FBA-BC06-06E8292926CAQ35584058-8D52C6E8-FF7C-4D11-9D11-E91783648AFCQ35622444-9162B035-4B47-443B-87F9-D220919F9542Q35683807-EEBFFF44-370D-45A0-A318-B144F047F042Q35776951-9AEF49CB-42DD-4A12-BC5E-2D4C98330CA4Q35837665-981D321F-7630-4EF2-9145-1FAC6B602AC3Q35918469-5B6FEA52-20BA-437B-948F-461C415C87B3Q35958082-FC13EF51-053C-485E-BC4F-6B609E030A28Q35990530-C64D54CE-99DE-410B-9079-0F84739A1F92Q36014897-066C334B-5C62-4A57-8286-ED3293A01164Q36026424-FE7CD898-E3B8-4AF9-B307-C3813C9ED6F5Q36090532-D9318E44-E949-417D-8184-F69D0925D577Q36108605-68A0E938-38CC-46B1-BC72-582F40949CAEQ36169971-CB706320-C75A-430E-AB66-998BE0499287
P2860
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Anastrozole is superior to tam ...... ive advanced breast carcinoma.
@en
Anastrozole is superior to tam ...... ive advanced breast carcinoma.
@nl
type
label
Anastrozole is superior to tam ...... ive advanced breast carcinoma.
@en
Anastrozole is superior to tam ...... ive advanced breast carcinoma.
@nl
prefLabel
Anastrozole is superior to tam ...... ive advanced breast carcinoma.
@en
Anastrozole is superior to tam ...... ive advanced breast carcinoma.
@nl
P2093
P2860
P1433
P1476
Anastrozole is superior to tam ...... ive advanced breast carcinoma.
@en
P2093
Arimidex Writing Committee
B Thürlimann
Investigators Committee Members
J Bonneterre
J F Robertson
J M Nabholtz
M Steinberg
M von Euler
P2860
P304
P356
10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y
P407
P577
2001-11-01T00:00:00Z